Clinical Trial Update: A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 1/2 study of NKT2152, a HIF2α inhibitor, in patients with advanced clear cell renal cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• NKT2152

Snippet

Sponsor: NiKang Therapeutics, Inc. | Conditions: ccRCC, Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED